{
  "test_cases": {
    "breast_cancer_her2_positive": {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT12345678",
          "briefTitle": "Study of Novel Therapy in HER2-Positive Breast Cancer",
          "officialTitle": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer"
        },
        "conditionsModule": {
          "conditions": [
            "HER2-Positive Breast Cancer",
            "Metastatic Breast Cancer"
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "INCLUSION CRITERIA:\n- Histologically confirmed HER2-positive metastatic breast cancer\n- Measurable disease per RECIST 1.1\n- ECOG performance status 0-1\n- Adequate organ function\n\nEXCLUSION CRITERIA:\n- Prior treatment with Trastuzumab Deruxtecan\n- Active brain metastases\n- Pregnancy or breastfeeding"
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "type": "Drug",
              "name": "Trastuzumab Deruxtecan",
              "description": "Novel antibody-drug conjugate targeting HER2"
            },
            {
              "type": "Drug", 
              "name": "trastuzumab",
              "description": "Standard HER2-targeted therapy"
            },
            {
              "type": "Drug",
              "name": "taxane",
              "description": "Chemotherapy backbone"
            }
          ]
        },
        "descriptionModule": {
          "briefSummary": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy."
        }
      }
    }
  }
}